nach oben

Clinical and Translational Oncology

Erschienen in:

01.07.2013 | Editorial

Should be NICE have a Spanish NICE?

verfasst von: J. Feliu, E. Espinosa

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Excerpt

Cancer is the second leading cause of death in Spain, accounting for 25 % of all deaths. One out of three men and one out of four women will have a cancer during their lives, a proportion that will increase with progressive ageing of the general population. …

Jönsson B, Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007;18(Suppl 3):1–77.

Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol N, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12:933–80.PubMedCrossRef

Elkin EB, Bach PB. Cancer’s next frontier. Addressing high and increasing costs. JAMA. 2010;303:1086–7.PubMedCrossRef

Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317–9.PubMedCrossRef

Sánz-Ortiz J. Chemotherapy at the end of life: up until when? Clin Transl Oncol. 2012;14:667–74.PubMedCrossRef

National Institute for Health and Care Excellence. http://www.nice.org.uk/aboutnice/whoweare/who_we_are.jsp.

Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103:16–20.PubMedCrossRef

European Medicines Agency. Answers from the CHMP Scientific Advisory Group (SAG) for Oncology for revision of the anticancer guideline. EMA/768937/2012.

Pouvourville G. HAS to be NICE. Eur J Health Econ 2013 (in press).

10.

Willemse PHB, Tjan-Heijnen VCG. Difficult decisions in the cost-effectiveness analysis of new cancer treatments. EJHPP. 2009;15:50–3.

11.

Theriault RL. Health care cost: how do we decide value? When do we decide? How do we particularize the decisions? Oncologist. 2012;17:157–9.PubMedCrossRef

12.

Kirkdale R, Krell J, O'Hanlon C, Tuthill M, Waxman J. The cost of a QALY. QJ Med. 2010;103:715–20.CrossRef

13.

Fojo T, Grady C. How much is life worth: cetuximab non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101:1044–8.PubMedCrossRef

14.

Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235–51.PubMedCrossRef

15.

Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50.000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349–56.PubMedCrossRef

Titel: Should be NICE have a Spanish NICE?
verfasst von: J. Feliu
E. Espinosa
Publikationsdatum: 01.07.2013
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 7/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1051-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Should be NICE have a Spanish NICE?

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

Management and outcome of ovarian malignancy complicating pregnancy: an analysis of 41 cases and review of the literature

Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers

Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma

Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer

Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie